IRIS PubliCatt

Fianchi, Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.499
NA - Nord America 4.023
AS - Asia 1.445
SA - Sud America 32
AF - Africa 25
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.043
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.997
DE - Germania 1.945
SE - Svezia 795
CN - Cina 763
UA - Ucraina 357
SG - Singapore 348
IT - Italia 311
PL - Polonia 252
IE - Irlanda 193
FR - Francia 189
GB - Regno Unito 148
ID - Indonesia 119
FI - Finlandia 96
IN - India 95
RU - Federazione Russa 93
TR - Turchia 35
JP - Giappone 25
NL - Olanda 24
BE - Belgio 21
CA - Canada 17
ES - Italia 16
CI - Costa d'Avorio 15
AU - Australia 13
HK - Hong Kong 13
BR - Brasile 12
KR - Corea 10
IR - Iran 9
CZ - Repubblica Ceca 8
MX - Messico 8
RO - Romania 8
VN - Vietnam 8
LT - Lituania 7
AT - Austria 6
NO - Norvegia 6
TH - Thailandia 6
BG - Bulgaria 5
CL - Cile 5
CO - Colombia 5
IL - Israele 5
ZA - Sudafrica 5
GR - Grecia 4
HU - Ungheria 4
AR - Argentina 3
CH - Svizzera 3
EC - Ecuador 3
EG - Egitto 3
EU - Europa 2
HR - Croazia 2
LU - Lussemburgo 2
MY - Malesia 2
NZ - Nuova Zelanda 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BO - Bolivia 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MA - Marocco 1
MD - Moldavia 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PY - Paraguay 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UY - Uruguay 1
Totale 10.043
Salva come PNG Salva come JPEG
Città #
Chandler 811
Ashburn 274
Singapore 269
Jacksonville 260
Warsaw 248
San Mateo 184
Dublin 181
Ann Arbor 172
Dearborn 159
Nanjing 155
Wilmington 141
Houston 120
Nürnberg 120
Jakarta 117
Woodbridge 108
New York 107
Beijing 87
Fairfield 80
Milan 79
Boston 76
Bremen 75
Moscow 72
Seattle 67
Lawrence 66
Munich 65
Cattolica 63
Nanchang 53
Redwood City 50
Zhengzhou 46
Redmond 45
Marseille 41
Los Angeles 38
Shenyang 38
Princeton 37
Kunming 36
Shanghai 36
Hangzhou 35
Lancaster 32
Leawood 30
Cambridge 29
Chicago 28
Hebei 26
Auburn Hills 25
Izmir 24
Boardman 23
Rome 22
Brussels 21
Jiaxing 21
Mountain View 21
Tianjin 21
Augusta 19
Hefei 19
Norwalk 19
Falls Church 18
University Park 18
Guangzhou 17
Changsha 16
Chatsworth 16
Pune 16
Abidjan 15
Philadelphia 15
Jinan 13
Hong Kong 12
London 12
Frankfurt am Main 11
Fremont 11
Simi Valley 10
Helsinki 9
São Paulo 8
Toronto 8
Costa Mesa 7
Edinburgh 7
Lanzhou 7
Monmouth Junction 7
San Francisco 7
Washington 7
Enterprise 6
Hanoi 6
Kansas City 6
Lappeenranta 6
Ningbo 6
San Diego 6
San Jose 6
Taizhou 6
Tokyo 6
Amsterdam 5
Andover 5
Bari 5
Chengdu 5
Falkenstein 5
Nuremberg 5
Paris 5
Phoenix 5
Seoul 5
Budapest 4
Changchun 4
Columbus 4
Cuauhtémoc 4
Kish 4
Madrid 4
Totale 5.381
Salva come PNG Salva come JPEG
Nome #
Incidence of acute myeloid leukemia after breast cancer 336
Factors associated with mortality in bacteremic patients with haematologic malignancies 302
Factors associated with mortality in bacteremic patients with hematologic malignancies. 302
Fanconi anemia gene variants in therapy-related myeloid neoplasms 259
Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies 206
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 176
MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES 169
Factors associated with mortality in bacteremic patients with hematologic malignancies. 168
Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. 159
GSK3β down-regulation in Mesenchymal Stem Cells from patients with Myelodysplastic Syndrome. 159
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 141
DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA 140
Why methylation is not a marker predictive of response to hypomethylating agents 137
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 135
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 134
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 134
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 133
Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies 130
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 128
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. 126
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 125
Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies 123
Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia 122
Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. 119
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 115
Primary plasma cell leukemia followed by testicular plasmacytoma 113
All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients 111
Epigenetic changes in therapy-related MDS/AML 108
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency 108
in Higher-Risk Myelodysplastic Syndromes and Low Blast Count Acute Myeloid Leukemia: Results of the BMT-AZA Prospective Study 108
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 107
Similarities and differences between therapy-related and elderly acute myeloid leukemia 107
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 107
Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 105
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 104
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 103
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 103
. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. 99
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 99
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 97
Outcome of therapy-related myeloid neoplasms treated with azacitidine 95
Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report. 92
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 92
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 91
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 91
Clonal evolution in therapy-related neoplasms 90
Scedosporiosis in patients with acute leukemia: a retrospective multicenter report 89
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 89
Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies 87
Small lymphocytic lymphoma in a patient with Fabry disease 86
Caspofungin for the treatment of candidaemia in patients with haematological malignancies 86
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 86
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 85
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 84
Small lymphocytic lymphoma in a patient with Fabry disease 81
Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies 80
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 80
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 79
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 79
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 78
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 78
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 77
Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? 72
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 72
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 72
The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. 67
Current therapeutic approaches to fungal infections in immunocompromised hematological patients 67
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 67
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 66
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 66
Therapy-related myeloid neoplasms 65
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 63
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 62
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 61
Therapy-related myeloid neoplasms: Clinical perspectives 60
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 59
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 59
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 58
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 58
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 57
Dose-dependent effect of granulocyte transfusions in hematological patients with febrile neutropenia 57
Dose-dependent effect of granulocyte transfusions in hematological patients with febrile neutropenia 57
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 57
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 57
. Pulmonary aspergillosis: lights and shadows 56
The role of neutrophils in the development and outcome of zygomycosis in haematological patients 55
Common Genetic Polymorphisms within NFκB-Related Genes and the Risk of Developing Invasive Aspergillosis 54
Polymorphisms within the ARNT2 and CX3CR1 Genes Are Associated with the Risk of Developing Invasive Aspergillosis 53
Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience 53
ZYGOMYCOSIS: Current approaches to management of patients with haematological malignancies. 52
Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient 50
Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium 47
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 46
Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study) 46
Breakthrough zygomycosis and voriconazole 41
Polymorphisms within the TNFSF4 and mapkapk2 loci influence the risk of developing invasive aspergillosis: A two-stage case control study in the context of the aspbiomics consortium 41
Disseminated geosmithia argillacea infection in a patient with ph-positive acute lymphoblastic leukemia. Case report and literature review 41
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 39
Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium 38
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry 37
Totale 9.760
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.960
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020626 0 0 0 0 0 0 125 59 113 106 117 106
2020/20211.089 40 93 24 88 136 118 133 29 105 58 231 34
2021/20221.028 108 69 12 43 75 49 26 164 55 85 141 201
2022/20232.152 270 303 185 382 151 255 81 182 232 17 72 22
2023/2024972 50 272 32 31 29 195 53 23 12 27 126 122
2024/2025627 60 75 160 49 209 59 15 0 0 0 0 0
Totale 10.157